Physiology of chemotherapy-induced emesis and antiemetic therapy. Predictive models for evaluation of new compounds

Drugs

Volumn 53, Issue 2, 1997, Pages 206-234

  Veyrat Follet, Christine ^a,b   Farinotti, Robert ^b   Palmer, Jonathan L ^c  

^a Glaxo Wellcome   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3 (5 METHYL 1H IMIDAZOL 4 YL) 1 (1 METHYL 1H INDOL 3 YL) 1 PROPANONE; ANTIEMETIC AGENT; ANTIHISTAMINIC AGENT; ANTINEOPLASTIC AGENT; BEMESETRON; BENZODIAZEPINE DERIVATIVE; CANNABINOID; CORTICOSTEROID; DAZOPRIDE; DOMPERIDONE; FLUPHENAZINE; GRANISETRON; HALOPERIDOL; METOCLOPRAMIDE; ONDANSETRON; RENZAPRIDE; SEROTONIN; SEROTONIN ANTAGONIST; SEROTONIN RECEPTOR; SUBSTANCE P; SULPIRIDE; TIAPRIDE; TROPISETRON; UNINDEXED DRUG; ZACOPRIDE; ZATOSETRON;

BRAIN REGION; CENTRAL NERVOUS SYSTEM DISEASE; CHEMORECEPTOR; CHEMOTHERAPY; CLINICAL TRIAL; EXTRAPYRAMIDAL SYNDROME; GASTROINTESTINAL MOTILITY; HUMAN; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MECHANORECEPTOR; MOTION SICKNESS; NAUSEA; NONHUMAN; ORAL DRUG ADMINISTRATION; POSTOPERATIVE CARE; RADIOTHERAPY; REVIEW; SENSORY NERVE; SUBCUTANEOUS DRUG ADMINISTRATION; VESTIBULAR LABYRINTH; VOMITING;

ANIMALIA; EMESIS;

EID: 0031014883     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199753020-00003     Document Type: Review

References (141)

1. Barnes JH. The physiology and pharmacology of emesis. Mol Aspects Med 1984; 7: 397-508
2. Laszlo J. Nausea and vomiting as major complications of cancer chemotherapy. Drugs 1983; 25 Suppl. 1: 1-7
3. Kris MG, Gralla RJ, Clark RA, et al. Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. J Clin Oncol 1985; 3 (10): 1379-84
4. Martin M, Diaz-Rubio E, Sanchez A, et al. The natural course ot emesis after carboplatin treatment. Acta Oncol 1990; 29 (5): 593-5
5. Fetting JH, Grochow LB, Folstein MF, et al. The course of nausea and vomiting after high-dose cyclophosphamide. Cancer Treat Rep 1982; 66: 1487-93
6. 3 receptor antagonists: an overview of their present status and future potential in cancer therapy-induced emesis. Drugs 1991 42 (4): 551-68
7. Borison HL, Wang SC. Physiology and pharmacology of vomiting. Pharmacol Rev 1953; 5: 193-230
8. Borison HL. Electrical stimulation of the central nervous mechanism for vomiting in the cat. Am J Physiol Proc 1948; 155: 428
9. Borison HL, Wang SC. Functional localisation of central coordinating mechanism for emesis in cat. J Neurophysiol 1949; 12:305-13
10. Andrews PLR, Davis CJ. The mechanism of emesis induced by anti-cancer therapies. In Andrews PLR, Sanger GJ, editors. Emesis in anti-cancer therapy: mechanisms and treatment. Chapman and Hall: London, 1993: 113-61
11. Lang IM. Digestive tract motor correlates of vomiting and nausea. Can J Physiol Pharmacol 1990; 68: 242-53
12. Lang IM, Sarna SK, Dodds WJ. Pharyngeal, esophageal, and proximal gastric responses associated with vomiting. Am J Physiol 1993; 265: G963-72
13. Miller AD. Respiratory muscle control during vomiting. Can J Physiol Pharmacol 1990; 68: 237-41
14. Wang SC, Borison HL. Copper sulphate emesis: a study of afferent pathways from gastrointestinal tract. Am J Physiol 1951; 164: 520-6
15. Wang SC, Borison HL. A new concept of organization of the central emetic mechanism: recent studies on the sites of action of apomorphine, copper sulfate and cardiac glycosides. Gastroenterology 1952; 22 (1): 1-12
16. Borison HL, Brizzee KR. Morphology of emetic chemoreceptor trigger zone in cat medulla oblongata. Proc Soc Exp Biol Med 1951; 77: 38-42
17. Carpenter DO. Neural mechanisms of emesis. Can J Physiol Pharmacol 1990; 68: 230-6
18. Borison HL, McCarthy LE. Neuropharmacology of chemotherapy-induced emesis. Drugs 1983; 25 Suppl. 1: 8-17
19. McCarthy LE, Borison HL. Cisplatin-induced vomiting eliminated by ablation of the area postrema in cats. Cancer Treat Rep 1984; 68 (2): 401-4
20. Andrews PLR, Davis CJ, Bingham S, et al. The abdominal innervation and the emetic reflex: pathways, pharmacology, and plasticity. Can J Physiol Pharmacol 1990; 68: 325-45
21. Borison HL, Borison R, McCarthy LE. Role of the area postrema in vomiting and related functions. Fed Proc 1984; 43: 2955-8
22. Mitchelson F. Pharmacological agents affecting emesis: a review (Pt 1). Drugs 1992; 43 (3): 295-315
23. Andrews PLR, Rapeport WG, Sanger GJ. Neuropharmacology of emesis induced by anti-cancer therapy. Trends Pharmacol Sci 1988; 9: 334-41
24. 3 receptors antagonists injected into the area postrema inhibit cisplatin-induced emesis in the ferret. Br J Pharmacol 1989; 97: 247-55
25. Nussey SS, Hawthorn J, Page SR, et al. Responses of plasma oxytocin and arginine vasopressin to nausea induced by apomorphine and ipecacuanha. Clin Endocrinol 1988; 28: 297-304
26. Rowe JW, Shelton RL, Helderman JH, et al. Influence of the emetic reflex on vasopressin release in man. Kidney Int 1979; 16: 729-35
27. Fisher RD, Rentschler RE, Nelson JC, et al. Elevation of plasma antidiuretic hormone (ADH) associated with chemotherapy-induced emesis in man. Cancer Treat Rep 1982; 66: 25-9
28. Edwards CM, Carmichael J, Baylis PH, et al. Arginine vasopressin - a mediator of chemotherapy induced emesis? Br J Cancer 1989; 59: 467-70
29. Triozzi PL, Laszlo J. Optimum management of nausea and vomiting in cancer chemotherapy. Drugs 1987; 34: 136-49
30. Cubeddu LX. Mechanisms by which cancer chemotherapeutic drugs induce emesis. Semin Oncol 1992; 19 (6 Suppl. 15): 2-13
31. Hainsworth JD, Omura GA, Khojasteh A, et al. Ondansetron (GR38032F): a novel antiemetic effective in patients receiving a multiple day regimen of cisplatin chemotherapy. Am J Clin Oncol 1991; 14 (4): 336-40
32. Fox SM, Einhorn LH, Cox E, et al. Ondansetron versus ondansetron, dexamethasone, and chlorpromazine in the prevention of nausea and vomiting associated with multiple-day cisplatin chemotherapy. J Clin Oncol 1993; 11: 2391-5
33. Harding RK, Hugenholtz H, Keaney M, et al. Discrete lesions of the area postrema abolish radiation-induced emesis in the dog. Neurosci Lett 1985; 53: 95-100
34. Borison HL, Brand ED, Orkand RK. Emetic action of nitrogen mustard (mechlorethamine hydrochloride) in dogs and cats. Am J Physiol 1958; 192 (2): 410-6
35. Carl PL, Cubeddu LX, Lindley C, et al. Do humoral factors mediate cancer chemotherapy-induced emesis? Drug Metab Rev 1989: 21 (2): 319-33
36. King GL. Animals models in the study of vomiting. Can J Physiol Pharmacol 1990b; 68: 260-8
37. Peroutka SJ. Chemotherapeutic agents do not interact with neurotransmitter receptors. Cancer Chemother Pharmacol 1987; 19: 131-2
38. 1-adrenergic receptors. Cancer Chemother Pharmacol 1993; 33: 53-6
39. Costall B, Domeney AM, Naylor RJ, et al. Emesis induced by cisplatin in the ferret as a model for the detection of antiemetic drugs. Neuropharmacology 1987; 26(9): 1321-6
40. Smith WL, Callaham EM, Alpbin RS. The emetic action of centrally administered cisplatin in cats and its antagonism by zacopride. J Pharm Pharmacol 1988; 40: 142-3
41. Hawthorn J, Ostler KJ, Andrews PLR. The role of the abdominal visceral innervation and 5-hydroxytryptamine M-receptors in vomiting induced by the cytotoxic drugs cyclophosphamide and cis-platin in the ferret. Q J Exp Physiol 1988; 73: 7-21
42. Harris HL. Cytotoxic-therapy-induced vomiting is mediated via enkephalin pathways. Lancet 1982; 1: 714-6
43. Stewart DJ. Cancer therapy, vomiting, and antiemetics. Can J Physiol Pharmacol 1990; 68: 304-13
44. Alfieri AB, Cubeddu LX. Effects of inhibition of serotonin synthesis on 5-hydroxyindoleacetic acid excretion, in healthy subjects. J Clin Pharmacol 1994; 34: 153-7
45. Alfieri AB, Cubeddu LX. Treatment with para-chlorophenylalanine antagonises the emetic response and the serotonin-releasing actions of cisplatin in cancer patients. Br J Cancer 1995; 71: 629-32
46. Barnes NM, Barry JM, Costall B, et al. Antagonism by parachlorophenylalanine of cisplatin-induced emesis [abstract]. Br J Pharmacol 1987; 92: 649P
47. Gunning SJ, Hagan R, Tyers MB. Cisplatin induces biochemical and histological changes in the small intestine of the ferret [abstract]. Br J Pharmacol 1987; 90: 135P
48. Costall B, Domeney AM, Naylor RJ, et al. 5-hydroxytryptamine M-receptor antagonism to prevent cisplatin-induced emesis. Neuropharmacology 1986; 25 (8): 959-61
49. Miner WD, Sanger GJ, Turner DH. Comparison of the effect of BRL 24924. metoclopramide and domperidone on cisplatin-induced emesis in the ferret [abstract]. Br J Pharmacol 1986; 88: 374P
50. 3 receptors mediate cytotoxic drug and radiation-evoked emesis. Br J Cancer 1987; 56: 159-62
51. 3 receptor antagonist BRL 43694 [abstract]. Br J Pharmacol 1987a; 91 Suppl.: 418P
52. 3 receptors mediate cisplatin-induced emesis in dogs. Jpn J Pharmacol 1992; 59: 221-6
53. Miner WD, Sanger GJ. Inhibition of cisplatin-induced vomiting by selective 5-hydroxytryptamine M-receptor antagonism. Br J Pharmacol 1986; 88: 497-9
54. 3 receptor antagonist [abstract]. Br J Cancer 1987b; 56: 227
55. Bermudez J, Boyle EA, Miner WD, et al. The anti-emetic potential of the 5-hydroxytryptamine3 receptor antagonist BRL 43694. Br J Cancer 1988; 58: 644-50
56. 3 receptors and vagal afferents in copper sulfate- and cisplatin-induced emesis in monkeys. Eur J Pharmacol 1993; 249: 13-8
57. 3 receptor antagonist, can abolish emesis induced by cyclophosphamide or radiation in the ferret [abstract]. Br J Pharmacol 1987; 91: 417P
58. 4 receptor in zacopride- and copper sulphate-induced vomiting in the ferret. Eur J Pharmacol 1991; 204: 273-80
59. 3-receptor antagonist with anti-emetic properties. Br J Clin Pharmacol 1989; 27: 147-57
60. Du Bois A, Kriesinger-Schroeder H, Meerpohl HG. The role of serotonin as a mediator of emesis induced by different stimuli. Support Care Cancer 1995; 3: 285-90
61. Cubeddu LX, Hoffmann IS, Fuenmayor NT, et al. Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-indused nausea and vomiting. N Engl J Med 1990a; 322 (12): 810-6
62. Cubeddu LX, Hoffmann LS, Fuenmayor N. Serotonin and emesis - from animals to humans: a discussion of Professor Naylor's paper. Br J Cancer 1992a; 66 Suppl. XIX: S9-11
63. Cubeddu LX, Hoffmann IS, Fuenmayor NT, et al. Changes in serotonin metabolism in cancer patients: its relationship to nausea and vomiting induced by chemotherapeutic drugs. Br J Cancer 1992b; 66: 198-203
64. Cubeddu LX, O'Connor DT, Hoffmann I, et al. Plasma chromogranin A marks emesis and serotonin release associated with dacarbazine and nitrogen mustard but not with cyclophosphamide. Br J Cancer 1995a; 72: 1033-8
65. Cubeddu LX, O'Connor DT, Parmer RJ. Plasma chromogranin A: a marker of serotonin release and emesis associated with cisplatin chemotherapy. J Clin Oncol 13 1995b; (3): 681-7
66. Bargsten G, Grube D. Serotonin storage and chromogranins: an experimental study in rat gastric endocrine cells. J Histochem Cytochem 1992; 40 (8): 1147-55
67. Van Wijngaarden I, Tulp MThM, Soudijn W. The concept of selectivity in 5-HT receptor research. Eur J Pharmacol 1990; 188: 301-12
68. 4 receptors in copper sulfate-induced vomiting in dogs. Eur J Pharmacol 1994; 257: 47-52
69. Sancilio LF, Pinkus LM, Jackson CB, et al. Emetic activity of zacopride in ferrets and its antagonism by pharmacological agents. Eur J Pharmacol 1990; 181: 303-6
70. Wynn RL, Essien E, Thut PD. The effects of different antiemetic agents on morphine-induced emesis in ferrets. Eur J Pharmacol 1993; 241: 47-54
71. 3 receptors. Neuropharmacology 31 1992; (8): 735-42
72. 4 receptor: a place in the sun. Trends Pharmacol Sci 1992; 13: 141-5
73. Hoyer D, Clarke DE, Fozard JR, et al. VIIth International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol Rev 1994; 46 (2): 157-203
74. 1A receptor agonists as anti-emetics. In: Reynolds DJM, Andrews PLR, Davis CJ, editors. Serotonin and the scientific basis of anti-emetic therapy. Oxford: Oxford Clinical Communications, 1995: 222-7
75. Jovanovic-Micic D, Samardzic R, Beleslin DB. The role of α-adrenergic mechanisms within the area postrema in dopamine-induced emesis. Eur J Pharmacol 1995; 272: 21-30
76. Lawes INC. The origin of the vomiting response: a neuroanatomical hypothesis. Can J Physiol Pharmacol 1990; 68: 254-9
77. Cubeddu LX, Lindley CM, Weisel W, et al. Role of angiotensin II and vasopressin in cisplatin-induced emesis. Life Sci 1990b; 46: 699-705
78. Kucharczyk J, Harding RK. Regulatory peptides and the onset of nausea and vomiting. Can J Physiol Pharmacol 1990; 68: 289-93
79. McRitchie DA, Törk I. Distribution of substance P-like immunoreactive neurons and terminals throughout the nucleus of the solitary tract in the human brainstem. J Comp Neurol 1994; 343: 83-101
80. 1 receptor. Br J Pharmacol 1995; 115: 84-94
81. Sundler F, Alumets J, Häkanson R. 5-hydroxytryptamine-containing enterochromaffin cells: storage site of substance P. Acta Physiol Scand 1977; 452: 121-3
82. Tattersall FD, Rycroft W, Hargreaves RJ, et al. The tachykinine receptor antagonist CP-99,994 attenuates cisplatin induced emesis in the ferret. Eur J Pharmacol 1993; 250: R5-6
83. 1 receptor antagonist. CP-99,994, in ferrets. Eur J Pharmacol 1993; 249: R3-4
84. 1 receptor antagonist CP99,994. Neuropharmacology 1994; 33 (2): 259-60
85. 1 receptor antagonist GR203040. Br J Pharmacol 1995; 116: 3158-63
86. Adrian TH, Ferri GL, Bacarese-Hamilton AJ, et al. Human distribution and release of a putative new gut hormone, peptide YY. Gastroenterology 1985; 89: 1070-7
87. Harding RK, McDonald TJ. Identification and characterisation of the emetic effects of peptide YY. Peptides 1989; 10: 21-4
88. Perry MR, Rhee J, Smith WL. Plasma levels of peptide YY correlate with cisplatin-induced emesis in dogs. J Pharm Pharmacol 1994; 46: 553-7
89. Akwari OE. The gastrointestinal tract in chemotherapy-induced emesis: a final common pathway. Drugs 1983; 25 Suppl. 1: 18-34
90. Cubeddu LX, Hoffmann IS. Participation of serotonin on early and delayed emesis induced by initial and subsequent cycles of cisplatinum-based chemotherapy: effects of antiemetics. J Clin Pharmacol 1993; 33: 691-7
91. Fredrikson M, Hursti TJ, Steineck G, et al. Delayed chemotherapy-induced nausea is augmented by high levels of endogenous noradrenaline. Br J Cancer 1994; 70: 642-5
92. Sanger GJ. New antiemetic drugs. Can J Physiol Pharmacol 1990; 68: 314-24
93. Leslie RA, Shah Y, Thejomayen M, et al. The neuropharmacology of emesis: the role of receptors in neuromodulation of nausea and vomiting. Can J Physiol Pharmacol 1990; 68: 279-88
94. Lang IM, Sarna SK. The role of adrenergic receptors in the initiation of vomiting and ils gastrointestinal motor correlates. J Pharmacol Exp Ther 1992; 263 (1): 395-403
95. Craig JB, Powell BL, While DR, et al. Antiemetic therapy in patients treated with high-dose cytosine arabinoside. Oncology 1987; 44: 90-2
96. Gordon CJ, Pazdur R, Ziccarelli A, et al. Metoclopramide versus metoclopramide and lorazepum. Cancer 1989; 63: 578-82
97. Maher J. Intravenous lorazepam to prevent nausea and vomiting associated with cancer chemotherapy. Lancet 1981; 1: 91-2
98. Gaddum JH, Picarelli ZP. Two kinds of tryptamine receptor. Br J Pharmacol 1957; 12: 323-8
99. 3 receptors. Trends Neurosci 1986; 9: 424-8
100. Bradley PB, Engel G, Feniuk W, et al. Proposals for the classification and nomenclature of functional receptors for 5-hydroxytryptamine. Neuropharmacology 1986; 25 (6): 563-76
101. Richardson BP, Engel G, Donatsch P, et al. Identification of serotonin M-receptor subtypes and their specific blockade by a new class of drugs. Nature 1985; 316: 126-31
102. 3 receptor antagonists: a discussion of Professor Naylor's paper. Br J Cancer 1992a; 66 Suppl. 19: S12-3
103. Tyers MB. Pharmacology and preclinical antiemetic properties of ondansetron. Semin Oncol 1992b; 19 Suppl. 10: 1-8
104. Fozard JR. Neunmal 5-HT receptors in the periphery. Neuropharmacology 1984; 23 (12B): 1473-86
105. 3 receptor antagonist properties of ICS 205-930, GR 38032F and zacopride. J Pharmacol Exp Ther 1988; 248 (1): 197-201
106. 3 antagonists in the ferret [abstract]. Br J Pharmacol 1988; 95: 504P
107. 3 receptors. Br J Pharmacol 1988; 94: 397-412
108. 3 receptor antagonism by BRL 43694 (granisetron). Eur J Pharmacol 1989; 159: 113-24
109. 3 receptor antagonist: effect on the flare response to intradermal 5-HT in man. Br J Clin Pharmacol 1991; 32: 651P-2P
110. 3) antagonist, on ipecac-induced emesis in healthy men [abstract]. Clin Pharmacol Ther 1991; 49: 171
111. Fozard JR, Mobarok Ali ATM. Blockade of neuronal tryptamine receptors by metoclopramide. Eur J Pharmacol 1978; 49: 109-12
112. 3 receptors and cytotoxic drug-induced vomiting. Trends Pharmacol Sci 1987; 8: 44-5
113. 3 receptor antagonists. Oncology 1992; 49: 263-8
114. Borison HL, Borison R, McCarthy LE. Phylogenic and neurologic aspects of the vomiting process. J Clin Pharmacol 1981; 21: 23S-9S
115. Andrews PLR, Bhandari P. The 5-hydroxytryptamine receptor antagonists as antiemetics: preclinical evaluation and mechanism of action. Eur J Cancer 1993; 29A Suppl. 1: S11-6
116. Costall B, Domeney AM, Naylor RJ, et al. Fluphenazine, ICS 205-930 and dl-fenfluramine differentially antagonise drug-induced emesis in the ferret. Neuropharmacology 1990; 29 (5): 453-62
117. Schwartz SM, Goldberg J, Gidda JS, et al. Effect of zatosetron on ipecac-induced emesis in dogs and healthy men. J Clin Pharmacol 1994; 34: 250-4
118. Naylor RJ, Inall FC. The physiology and pharmacology of post-operative nausea and vomiting. Anesthesia 1994; 49 Suppl.: 2-5
119. Barnes NM, Bunce KT, Naylor RJ, et al. The actions of fenfanyl to inhibit drug-induced emesis. Neuropharmacology 1991; 30 (10): 1073-83
120. Wang SC, Glaviano VV. Locus of emetic action of morphine and hydergine in dogs. J Pharmacol Exp Ther 1954; 111: 329-34
121. 3) receptor antagonist zacopride in the ferret. J Pharmacol Exp Ther 1990a; 253 (3): 1034-41
122. 3 receptor agonism may be responsible for the emetic effects of zacopride in the ferret. Br J Pharmacol 1991; 103: 1011-2
123. Sancilio LF, Pinkus LM, Jackson CB, et al. Studies on the emetic and antiemetic properties of zacopride and its enantiomers. Eur J Pharmacol 1991; 192: 365-9
124. Feldberg W, Smith AN. Release of histamine by tryptamine and 5-hydroxytryptamine. Br J Pharmacol 1953; 8: 406-11
125. Tonnesen P. Intracutaneous and skin prick testing with serotonin and histamine. Allergy 1986; 41: 196-202
126. Orwin JM, Fozard JR. Blockade of the flare response to intradermal 5-hydroxytryptamine in man by MDL 72.222, a selective antagonist at neuronal 5-hydroxytryptamine receptors. Eur J Pharmacol 1986; 30: 209-12
127. Arnold BDC, Cooper SM, Rapeport WG. An investigation of 5-hydroxytryptamine induced axon reflex flares in man. Br J Clin Pharmacol 1988; 25: 126P-7P
128. Sohail S, Lettis S, Millson D. Comparison of an autoinjector device with conventional intradermal injection of 5-HT to produce a flare response in man [abstract]. Br J Clin Pharmacol 1991; 32: 662P
129. Heavey DJ, Barnes VF Orwin J, et al. Inhibition of 5-HT induced axon reflex flares by MDL 72422 [abstract]. Br J Clin Pharmacol 1986; 21 Suppl.: 558P
130. Fowler PA, Sweetland J, Lobo D, et al. The effect of ondansetron on the flare response produced by intradermal 5-HT. Br J Clin Pharmacol 1992; 34: 181P-2P
131. 3 receptor antagonist. Br J Clin Pharmacol 1988; 25: 106P-7P
132. Sweelland J, Lettis S, Fowler PA, et al. Duration of the inhibitory effect of intravenous ondansetron on intradermal 5-HT induced flare [abstract]. Br J Clin Pharmacol 1992; 33: 565P
133. Dunlop DJ, Young F, Soukop M, et al. The inhibition of 5-HT induced axon-reflex flare in patients undergoing treatment with granisetron (Kytril) by prophylaxis and intervention for cancer chemotherapy induced nausea and vomiting [abstract]. Ann Oncol 1990; 1 Suppl.: 110
134. Radomski JL, Hagan EC, Fuyal HN, et al. The pharmacology of ipecac. J Pharmacol Ther 1452; 104: 421-6
135. Reynolds JEF, editor. Martindale: the extra pharmacopeia. 30th ed. London: Pharmaceutical Press, 1993
136. 3 receptor antagonists. Br J Clin Pharmacol 1992; 33: 221P-2P
137. Minton N, Swift R, Lawlor C, et al. Ipecacuanha-induced emesis: a human model for testing antiemetic drug activity. Clin Pharmacol Ther 1993; 54 (1): 53-7
138. Markham A, Sorkin EM. Ondansetron: an update of its therapeutic use in chemotherapy-induced and postoperative nausea and vomiting. Drugs 1993; 45 (6): 931-52
139. 3-receptor antagonists. Br J Clin Pharmacol 1994; 37: 525-30
140. Page SR, Peterson DB, Crosby SR, et al. The responses of arginine vasopressin and adrenocorticotrophin to nausea induced by ipecacuanha. Clin Endocrinol 1990; 33 (6): 761-70
141. Marty M, Richard A, d'Allens H, et al. Effet antiémétique de l'ondansetron au cours de cures répétées de chimiothérapies contenant du cisplatine. Bull Cancerol 1993; 80: 618-23